London’s Claret Capital Partners just closed its fourth European Growth Capital Fund at €575 million, a haul that smashes its original €500 million target and signals renewed investor appetite for the continent’s innovation economy.
The fund, which launches amid a tentative recovery in European venture financing, will steer capital toward life sciences, technology, and other high-impact industries. Since its founding in 2020, the independent growth debt manager has now accumulated €1.3 billion in total commitments.
Europe’s biotech sector still lags far behind the United States, which commands more than 60% of global venture funding compared to Europe’s 14% to 20% share. Yet oversubscribed vehicles like Claret’s suggest momentum may be shifting.
Managing partner David Bateman framed the result as validation of the firm’s strategy. “To have raised this amount not only validates our approach and track record but is also a massive vote of confidence for the European technology, life sciences and impact ecosystems,” he said.
Fund IV has already deployed capital into 27 portfolio companies. Recipients include Inventiva, a French biotech advancing an oral MASH therapy through phase 3 trials, Sweden’s Cinclus Pharma, which focuses on gastrointestinal drugs, and SIS Medical, a Swiss medtech producer of cardiovascular devices.
Roughly one-third of the new fund is already committed. Claret reports that deal flow remains brisk, with demand coming from companies seeking low-dilution financing to pursue international expansion, acquisitions, or product development.
Recent beneficiaries also include Carvolix, a French developer of AI-guided mini-robots and biomimetic implants for cardiology and stroke treatment, and Germany’s Wellster, which operates a physician-supervised digital platform for obesity care.
Johan Kampe, Claret’s managing partner, noted that tightening equity markets are pushing more founders toward non-dilutive options. As a result, he expects demand for flexible growth debt to keep accelerating.
To meet that demand, the firm plans to deepen its footprint across Europe’s innovation hubs. New team members have already landed in Paris, with a Berlin presence set to follow.
